Prompt Approval of Safe Generic Drugs Act

Cost and committee reports

Official records Congress.gov attaches to H.R. 9616.

• Constitutional authority statementThe sponsor’s statement of where the Constitution gives Congress the power to pass this bill. Statement by Ms. BARRAGAN, as printed in the Congressional Record (Vol. 170, No. 144, September 17, 2024, Page H5318):
  Article 1 Section 8 of the United States Constitution The single subject of this legislation is: To amend the Federal Food, Drug, and Cosmetic Act to provide for the prompt approval of drugs when safety information is added to labeling, and for other purposes.
  Source: Congress.gov, Congressional Record September 17, 2024 ↗

  Evidence

  Field in the Congress.gov record

  constitutionalAuthorityStatementText

  Statement length

  260 characters

  Congress.gov bill record

  H.R. 9616, 118th Congress

  Congress.gov API record

  https://api.congress.gov/v3/bill/118/hr/9616

  Record last updated by Congress.gov

  December 16, 2024

  PORKER copy retrieved

  September 14, 2026

  Stored copy, SHA-256 of the file

  edd32cb44330818114a36073dbd13995aca9515896aba526a203d2b7f07e0978

  PORKER shows the statement exactly as printed, with the page markup removed. It is the sponsor’s claim; it is not a legal finding.

Congress.gov’s record for this bill does not list a CBO cost estimate or a committee report (as of December 16, 2024). Not every bill gets one.

From the Congress.gov bill record for H.R. 9616, last updated December 16, 2024. PORKER’s copy was retrieved September 14, 2026 and is refreshed nightly. Open “Evidence” on any line for the record, field and file fingerprint.